Arecor extends collaboration deal with US biotech

Under the collaboration, Arecor will leverage its Arestat technology to develop liquid formulations of two proprietary novel products

Arecor - Arecor extends collaboration deal with US biotech

Arecor Limited has extended a multi-product collaboration with a US-based biotech company to develop products for oncology and a rare genetic orphan condition.

Under the collaboration, Arecor said it will leverage its Arestat technology to develop liquid formulations of two proprietary novel products, while its partner is currently funding the development work and has an option to acquire the formulations and associated intellectual property under separate milestone-bearing licenses at pre-agreed financial terms.

READ: Arecor achieves important second, contractual milestone with one of its pharmaceutical partners

Arestat is a formulation technology designed to enhance the properties of therapeutic proteins and peptides.

"This multi-collaboration with a fast growing US biotech company demonstrates the adaptability of the Arestat platform”, said Arecor chief executive Sarah Howell.

“Not only do these key products represent Arestat’s ability to support the development of clinical stage assets across a range of therapeutic areas, but also demonstrate the potential of the technology to deliver superior liquid formulations of novel format proteins, further expanding and advancing the application of Arecor’s expertise across the spectrum of product development”, she added.

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Arecor named herein, including the promotion by the Company of Arecor in any Content on the Site, the Company receives from said issuer annual...


Hikma Pharmaceuticals and Arecor strike a second strategic partnership deal

Arecor Limited's Sarah Howell talks to Proactive London about the announcement to expand their agreement with Hikma Pharmaceuticals PLC (LON:HKMA) to co-develop ready-to-administer injectable medicines in the US to a second product. As Howell explains, this deal follows on from the first...

5 days, 8 hours ago

2 min read